Investors

About Aldeyra

Aldeyra Therapeutics is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. The company's lead product, ADX-102, is an aldehyde trap in development for ocular and systemic inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism.

Press Releases

Nov 9, 2017
Nov 7, 2017
Nov 2, 2017
Oct 25, 2017
Oct 24, 2017

Corporate Presentation


Events


Scientific Posters & Presentations